Lung / Breast Cancer Study

Study Details

Participants in this clinical trial will receive a one-time, intravenous administration of the investigational drug. The study will closely monitor the drug’s impact on tumor size, progression, and overall patient health through regular assessments conducted by a team of medical professionals.

During the trial, participants will attend scheduled visits for evaluations and to track changes in their condition. The study aims to determine the drug’s efficacy in reducing tumor size and improving outcomes for individuals with non-small cell lung cancer or triple-negative breast cancer.

Interventions:

One-time, intravenous administration of the investigational drug targeting tumors associated with non-small cell lung cancer and triple-negative breast cancer.

Do you meet the criteria and want to join the study?

If you meet the criteria and are interested in contributing to this important research, you may qualify for this study. For more information or to discuss your eligibility, please contact the Haltha team at Haltha Connect.